期刊文献+

经尿道膀胱肿瘤等离子整块剜除术与传统电切术的对比研究 被引量:14

Comparative analysis of transurethral en-bloc resection of bladder tumor byplasma and transurethral resection of bladder tumor
在线阅读 下载PDF
导出
摘要 目的:对比经尿道膀胱肿瘤等离子整块剜除术(TeURBT)与传统经尿道膀胱肿瘤电切术(TURBT)的疗效及安全性。方法:选取2017年1月-2018年10月诊断为非肌层浸润性膀胱癌,行经尿道膀胱肿瘤切除术的患者232例,其中行经尿道膀胱肿瘤整块剜除术(TeURBT组)患者123例,行传统经尿道膀胱肿瘤电切术(TURBT组)患者109例,分别比较两组患者的手术时间、术中出血量、术中闭孔神经反射及膀胱穿孔的发生率,术后3个月、6个月、1年的肿瘤复发率。结果:TeURBT组平均手术时间长于TURBT组,差异有统计学意义(P<0.01),TeURBT组术中出血明显少于TURBT组(P<0.01),两组患者术中闭孔反射发生率差异无统计学意义,TeURBT组膀胱穿孔率低于传统TURBT组,差异有统计学意义(P<0.05),TeURBT组术后可以准确诊断分期,两组患者术后3个月复查均未发现肿瘤复发,两组患者术后6个月肿瘤复发率无显著差异,TeURBT组术后1年肿瘤复发率低于传统TURBT组,差异有统计学意义(P<0.05)。结论:经尿道膀胱肿瘤等离子整块剜除术可以准确获得肿瘤的病理分期,降低肿瘤复发率及进展风险,手术效果确切,值得临床推广应用。 Objective To compare the efficacy and safety of transurethral en-bloc resection of bladder tumor and traditional transurethral resection of bladder tumor(TURBT).Methods:From January 2017 to October 2018,232 patients with non-muscular invasive bladder cancer underwent transurethral cystectomy,and divided into transurethral en-bloc resection of bladder tumor group(TeURBT group,n=123),and traditional transurethral resection of blad⁃der tumor group(TURBT group,n=109).The operation time,blood loss,obturator nerve reflex and bladder perfo⁃ration were compared between the two groups.The recurrence rate of tumors at 3rd month,6th month and 1st year af⁃ter operation were compared between the two groups.Results:The average operation time of TeURBT group was significantly longer than that of TURBT group(P<0.01).Intraoperative bleeding in TeURBT group was signifi⁃cantly less than that in TURBT group(P<0.01).There was no significant difference in the incidence of obturator reflex between the two groups.The bladder perforation rate in TeURBT group was significantly lower than that in tra⁃ditional TURBT group(P<0.05).Postoperative pathological examination in TeURBT group could accurately diag⁃nose the stage of bladder cancer.No recurrence of tumors was found in the two groups after 3 months of follow-up.There was no significant difference in tumor recurrence rate between the two groups at 6th month after operation.The recurrence rate of one year after operation in TeURBT group was significantly lower than that in traditional TURBT group(P<0.05).Conclusion:Transurethral resection of bladder tumor by plasma can obtain accurate pathological stage and reduce the risk of recurrence and progression.The results of the operation are accurate and worthy of clinical application.
作者 王伟 周红庆 刘明生 邵涛 WANG Wei;ZHOU Hongqing;LIU Mingsheng;SHAO Tao(Department of Urology,Qujing First People's Hospital of Yunnan Province,Qujing 655000,China)
出处 《微创泌尿外科杂志》 2020年第2期115-119,共5页 Journal of Minimally Invasive Urology
关键词 膀胱肿瘤 经尿道膀胱肿瘤整块剜除术 膀胱肿瘤电切术 bladder tumor transurethral en-bloc resection of bladder tumor transurethral resection of bladder tumor
  • 相关文献

参考文献5

二级参考文献55

  • 1孙圣坤,宋兵,宋勇,许勇,徐阿祥,张旭.超声引导闭孔神经阻滞在膀胱肿瘤电切中的应用[J].微创泌尿外科杂志,2013,2(1):76-78. 被引量:5
  • 2宋伟宁,徐阿祥,孙圣坤,杨国强,许勇,杜国防,徐真蕊,张旭.经尿道针状电极膀胱部分切除术治疗膀胱尿路上皮癌(附4例报告)[J].微创泌尿外科杂志,2013,2(6):396-398. 被引量:15
  • 3Witjes J A, Hendricksen K. Intravesical pharmaco- therapy for non-muscle-invasive bladder cancer: a criti- cal analysis of currently available drugs, treatment schedules, and long-term results[J]. Eur Urol, 2008, 53(1) : 45-52.
  • 4Ahn J J, McKiernan J M. New agents for bacillus Calmette-Gu:rin-refractory bladder cancer [J]. Urol Clin North Am, 2013, 40(2): 219-232.
  • 5Jones G, Cleves A, Wilt T J, et al. lntravesical gem- citabine for non-muscle invasive bladder cancer[J]. go- chrane Database Syst Rev, 2012, 1 : CD009294.
  • 6Su D, Jiao S C, Wang l J, et al. Efficacy of nimotu zumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer[J]. Tumour Biol, 2014, 35(3):2313-2318.
  • 7Li W, Wang H, Li X. Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta anal- ysis of randomized controlled trials[J]. Curr Med Res Opin, 2013, 29(11): 1443-1452.
  • 8Tomita Y, Saito T, Okadome M, et al. The safety and efficacy of eisplatin plus gemcitabine in recurrent ovari- an cancer[J]. IntJ Clin Oncol, 2014, 19(4): 662- 666.
  • 9Iwasaki K, Obara W, Kato Y, et al. Neoadjuvant gemcitabine plus earboplatin for locally advanced blad- der cancer[J]. Jpn J Clin Oncol, 2013, 43(2) : 193- 199.
  • 10Gontero P, Frea B. Actual experience and future devel- opment of gemcitabine in superficial bladder cancer[J]. Ann Oncol, 2006, 17(Suppl 5): 123-128.

共引文献64

同被引文献128

引证文献14

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部